Vortioxetine for Anxiety Disorders

Guideline Position on Vortioxetine

The Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology explicitly excludes vortioxetine from their 2023 social anxiety disorder guideline recommendations 1, 2
Vortioxetine was not included in the guideline due to inadequate study, according to the Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology 2

SSRIs demonstrate high efficacy (NNT=4.70) with safety profiles comparable to placebo for social anxiety disorder, as recommended by the Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology 1, 2
SNRIs show comparable efficacy (NNT=4.94) and can be considered when SSRIs fail or are not tolerated, according to the Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology 1, 2